KEGG   DRUG: Blinatumomab
Entry
D09325                      Drug                                   
Name
Blinatumomab (USAN/INN);
Blinatumomab (genetical recombination) (JAN);
Blincyto (TN)
Product
BLINCYTO (Amgen)
Formula
C2367H3577N649O772S19
Exact mass
54052.5286
Mol weight
54085.89
Remark
Therapeutic category: 4291
ATC code: L01FX07
Product: D09325<JP/US>
Efficacy
Antineoplastic, Anti-CD19 and CD3 antibody
  Disease
B-cell precursor acute lymphoblastic leukemia (Philadelphia chromosome-negative) [DS:H00001]
  Type
Monoclonal antibody, bispecific antibody
Target
CD19 [HSA:930] [KO:K06465]
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
hsa04660  T cell receptor signaling pathway
hsa04662  B cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX07 Blinatumomab
      D09325  Blinatumomab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Blinatumomab
    D09325  Blinatumomab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D09325  Blinatumomab (USAN/INN); Blinatumomab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3
     D09325  Blinatumomab (USAN/INN) <JP/US>
    CD19
     D09325  Blinatumomab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09325
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09325
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D09325
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09325
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D09325
Other DBs
CAS: 853426-35-4
PubChem: 96026005

» Japanese version   » Back

  All links  
Ontology (9)   
   KEGG BRITE (9)   
Disease (1)   
   KEGG DISEASE (1)   
Chemical substance (1)   
   PubChem (1)   
Gene (8)   
   KEGG ORTHOLOGY (4)   
   KEGG GENES (4)   
All databases (19)   

Download RDF
DBGET integrated database retrieval system